Gambro AB Product Pipeline Analysis

SUMMARY

Gambro AB Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Gambro AB's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

TABLE OF CONTENTS

1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 8
2 Company Snapshot 9
2.1 Key Information 9
2.2 Company Overview 9
2.3 Financial Performance 9
3 Business Description 10
3.1 Business Overview 10
3.2 Gambro BCT 10
3.2.1 Overview 10
3.2.2 Financials 10
3.2.3 Market View 10
3.2.4 Key Strategies 10
3.3 Renal Care 11
3.3.1 Overview 11
3.3.2 Financials 11
3.3.3 Market View 11
3.3.4 Key Strategies 11
3.4 Major Products and Services 12
3.4.1 Overview 12
4 History 13
5 Business Strategy 15
5.1 Mission Statement 15
5.2 Strategy 15
5.3 Corporate Social Responsibility 15
5.3.1 Overview 15
6 Value Chain Analysis 16
6.1 Manufacturing 16
6.1.1 In House Manufacturing 16
6.2 Product Development 17
6.2.1 Regulatory Approvals 17
6.2.2 Clinical Trials 17
6.2.3 Research and Development 17
6.3 Sales and Marketing 17
6.3.1 Partnerships and Alliances 17
6.3.2 Licensing Agreements 17
7 Competitors 18
8 Key Employees 19
9 Key Employee Biographies 20
10 Company Statement 21
11 Locations And Subsidiaries 23
11.1 Head Office 23
11.2 Other Locations & Subsidiaries 23
12 Recent Developments 25
12.1 Strategy And Business Planning 25
12.1.1 Apr 17, 2008: Gambro Opens Bloodline Manufacturing Facility In Czech Republic 25
12.1.2 Mar 19, 2008: Gambro Signs Agreement With Debiotech On Peritoneal Dialysis 25
12.2 Research And Development 26
12.2.1 Mar 19, 2008: Gambro Signs Agreement With Debiotech On Peritoneal Dialysis 26
12.3 Corporate Communications 26
12.3.1 Jan 21, 2008: Gambro Appoints SVP, Global Quality Assurance And Regulatory Affairs 26
12.4 Product News 27
12.4.1 Feb 27, 2008: Gambro Receives 510(k) Clearance For Prismaflex System 3.20 Software 27
12.5 Other Significant Developments 27
12.5.1 May 20, 2008: Gambro Donates Dialysis Equipment To Help Earthquake Victims In Sichuan, China 27
13 Gambro AB Pipeline Products 28
13.1 Gambro AB Product Pipeline Analysis 28
13.1.1 Gambro AB Pipeline Products By Equipment Type 28
13.1.2 Gambro AB Pipeline Products By Development Stage 29
13.1.3 Gambro AB Pipeline Products By Therapy Area 30
13.2 BiCart Select 30
13.2.1 Product Description 30
13.2.2 Product Status 30
13.3 BiCart 30
13.3.1 Product Description 31
13.3.2 Product Status 31
13.4 Serena cycler 31
13.4.1 Product Description 31
13.4.2 Product Status 32
13.5 Gambro PDCATH- Self locating 32
13.5.1 Product Description 32
13.5.2 Product Status 32
13.6 Prismacomfort 32
13.6.1 Product Description 32
13.6.2 Product Status 33
13.7 AK 200 ULTRA 33
13.7.1 Product Description 33
13.7.2 Product Status 33
13.8 AK 95 S 33
13.8.1 Product Description 33
13.8.2 Product Status 34
13.9 AK 96 34
13.9.1 Product Description 34
13.9.2 Product Status 34
13.10 CATHcarry 34
13.10.1 Product Description 34
13.10.2 Product Status 35
13.11 Softpac 35
13.11.1 Product Description 35
13.11.2 Product Status 35
13.12 blunt needles 35
13.12.1 Product Description 36
13.12.2 Product Status 36
13.13 Prismaccess with Dolphin Protect 36
13.13.1 Product Description 36
13.13.2 Product Status 36
14 Appendix 37
14.1 Methodology 37
14.1.1 Coverage 37
14.1.2 Secondary Research 38
14.1.3 Primary Research 38
14.1.4 Expert Panel Validation 39
14.2 Contact Us 39
14.3 About Global Markets Direct 39
14.4 Disclaimer 39

1.1 List of Tables
Table 1: Gambro AB,Key Facts, 2005 9
Table 2: Gambro AB, Key Employees, 2005 19
Table 3: Gambro AB, Other Locations 23
Table 4: Gambro AB Pipeline Products by Equipment Type 28
Table 5: Gambro AB Pipeline Products By Development Stage 29
Table 6: Gambro AB Pipeline Products By Therapy Area 30

1.2 List of Figures
Figure 1: Gambro AB, Value Chain Analysis 16
Figure 2: Gambro AB Pipeline Products By Development Stage 29
Figure 3: Global Markets Direct Methodology 37